Last updated on February 2018

Expansion Study to Evaluate the Efficacy and Safety of HM95573 in BRAF KRAS or NRAS Mutant Solid Cancers


Brief description of study

This study evaluates the anti-tumor efficacy and safety of single agent HM95573 administered in patients with solid tumors harboring mutations in either BRAF, KRAS or NRAS gene.

Clinical Study Identifier: NCT03118817

Contact Investigators or Research Sites near you

Start Over

Chungbuk national university hospital

Korea, Republic of, Chungcheongbuk-do
Cheongju, Korea, Republic of
  Connect »